Amanda Nizam, Associate Staff of Genitourinary Medical Oncology at Cleveland Clinic, shared on X:
“With FDA approval of perioeprative EV+durvalumab for cis-ineligible MIBC today, how do oncologists feel about EV+P or EV+D?
- How many neoadjuvant cycles of EV are needed?
- Is adjuvant EV needed? In which patients?
- What to do for patients without pathologic downstaging?”
Continue exploring:
FDA Approves Durvalumab Plus Enfortumab Vedotin for Muscle-Invasive Bladder Cancer
